{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urinary-tract-infection-lower-women/prescribing-information/trimethoprim/","result":{"pageContext":{"chapter":{"id":"b42d0bbc-d0ac-52c7-83bf-5fc7a76a38dc","slug":"trimethoprim","fullItemName":"Trimethoprim","depth":2,"htmlHeader":"<!-- begin field 820d2e04-d6cd-4c53-adeb-a71c00ab5e78 --><h2>Trimethoprim</h2><!-- end field 820d2e04-d6cd-4c53-adeb-a71c00ab5e78 -->","summary":"","htmlStringContent":"<!-- begin item 6437e3bb-1c42-42fb-8a24-a71c00ab5ee9 --><!-- end item 6437e3bb-1c42-42fb-8a24-a71c00ab5ee9 -->","topic":{"id":"4205a2dd-1d74-53f2-90f4-5239307d2883","topicId":"7e36f7cd-e707-44db-a683-f4197a84b187","topicName":"Urinary tract infection (lower) - women","slug":"urinary-tract-infection-lower-women","lastRevised":"Last revised in October 2020","chapters":[{"id":"96f75303-a8ae-50a0-9d5c-e5a9b96e67f1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"cafb451d-db29-558a-a6cc-20d82dde3df9","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"14a65465-7aa4-5024-bb53-b3b2099b526a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7b90ea0f-0f86-5457-965d-930656bd2f02","slug":"changes","fullItemName":"Changes"},{"id":"4f3fd7bc-437b-509c-9a2d-5318de2b1e8b","slug":"update","fullItemName":"Update"}]},{"id":"850e1193-41eb-50b7-b401-ac0396c6e585","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"18c79474-b4ac-50cd-801a-3738d79a1159","slug":"goals","fullItemName":"Goals"},{"id":"24f4bdf7-0aa4-5f6b-a117-2c3a7da00984","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6b590746-634f-5a0c-b995-5f98bd9c6f0d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4c2be4f2-9e65-53d3-8ff6-7534932e7dc6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"835cf60d-f7b4-57b8-97ee-607930381034","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a526f295-371c-52d5-bd46-93333947aade","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"28adde3c-64d3-5e21-8797-08c56ab570c5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"4a732f85-1f37-5288-a872-611c3528c53e","slug":"definition","fullItemName":"Definition"},{"id":"8e922399-2c9d-5777-9660-944733f631f5","slug":"causes","fullItemName":"Causes"},{"id":"8fa46cfc-d97b-5218-847f-9553a7ce2854","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c9ad7aa8-f54d-55a8-b6f1-804d616de2b4","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a176b8d4-1d8f-5f62-935e-4f6fc4696153","slug":"complications","fullItemName":"Complications"}]},{"id":"03286f6f-e3d8-5889-8453-1db9ffb07914","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ec9700ef-7ba2-524e-868a-3dc60b345625","slug":"when-to-suspect-uti","fullItemName":"When to suspect UTI"},{"id":"182ae581-d75a-507d-8146-e0d7d26dcad8","slug":"assessment","fullItemName":"Assessment"},{"id":"5dfac6cd-ec1e-5d54-98a4-a65cf57457d9","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"6d45128d-30db-5879-917a-4a6e682fa7e9","fullItemName":"Management","slug":"management","subChapters":[{"id":"a72789b5-d51e-5516-8ab1-942aae1e0fe8","slug":"uti-no-visible-haematuria-not-pregnant-or-catheterized","fullItemName":"Scenario: UTI  (no visible haematuria, not pregnant or catheterized)"},{"id":"91dbd4da-8761-5e78-9eb2-a773cc7d2764","slug":"uti-with-visible-or-non-visible-haematuria","fullItemName":"Scenario: UTI  with visible or non-visible haematuria"},{"id":"3e093a06-3197-58a5-8c61-94586835adba","slug":"recurrent-uti-no-visible-haematuria-not-pregnant-or-catheterized","fullItemName":"Scenario: Recurrent UTI  (no visible haematuria, not pregnant or catheterized)"},{"id":"09df152e-ea9c-51c1-917c-5c4c01ab2fc8","slug":"uti-in-pregnancy-no-visible-haematuria","fullItemName":"Scenario: UTI in pregnancy  no visible haematuria"},{"id":"6d0e09de-6e28-53df-b01b-55fc899c0dd7","slug":"asymptomatic-bacteriuria-in-pregnancy","fullItemName":"Scenario: Asymptomatic bacteriuria in pregnancy"},{"id":"07efc80a-4963-5037-a8f2-c5b63d298205","slug":"uti-with-catheter-no-haematuria","fullItemName":"Scenario: UTI with catheter  no haematuria"}]},{"id":"7a32c4da-f7b1-5664-92e2-e1fdeca6361a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b42d0bbc-d0ac-52c7-83bf-5fc7a76a38dc","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"76a10025-1806-5d3b-96b0-72401241a768","slug":"nitrofurantoin","fullItemName":"Nitrofurantoin"},{"id":"625120b5-8124-549f-b13c-8b37bea158ff","slug":"pivmecillinam","fullItemName":"Pivmecillinam"},{"id":"bae5a7ea-ae42-56ba-82cc-74cbc655059f","slug":"fosfomycin","fullItemName":"Fosfomycin"},{"id":"e8dc8860-ec55-59c6-96c0-805260cb7172","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"e5121975-a684-5651-bf41-c324e815c0f5","slug":"cefalexin","fullItemName":"Cefalexin"}]},{"id":"332fba52-4a32-56f0-b721-29ac73f73e6d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"8f34f8fc-4bd2-54e3-87f0-a4a1394f3891","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9b392302-d709-5520-a890-25e10021e12b","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0d4bbe1a-f3f6-523c-85c0-1fae02dd5b27","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"84ca6e0f-7674-5f70-b099-406d5c783d89","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4ed139aa-715a-523d-8c0a-8f4e167d29df","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"067e363b-53be-5584-a0e9-2bf38e519877","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"045ecabb-df97-5df3-b561-ecddea4b7b17","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7a32c4da-f7b1-5664-92e2-e1fdeca6361a","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a5ee7769-fcba-5e2f-a1c9-2b6eb2fa71c0","slug":"trimethoprim","fullItemName":"Trimethoprim","depth":3,"htmlHeader":"<!-- begin field 6b3a4a5c-fdc3-4610-a3ac-a71c00abb219 --><h3>Trimethoprim</h3><!-- end field 6b3a4a5c-fdc3-4610-a3ac-a71c00abb219 -->","summary":"","htmlStringContent":"<!-- begin item 39bd7280-e58a-4aa3-acdf-a71c00abb25a --><!-- begin field acc42167-c396-4efa-8142-a71c00abb219 --><p><strong>Cautions and contraindications </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Arnold, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">ACOG, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NICE, 2018d</a>]</p><ul><li><strong>Do not prescribe trimethoprim in:</strong><ul><li>People with hypersensitivity to trimethoprim or any of the excipients.</li><li>People with severe hepatic insufficiency, or severe renal insufficiency.</li><li>People with megaloblastic anaemia or other blood dyscrasias.</li><li>Premature infants or children aged under 4 months.</li><li>Women who are pregnant.</li><li>People with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galacactose malabsorption.</li></ul></li><li><strong>Prescribe trimethoprim with caution in people:</strong><ul><li>With impaired renal function.</li><li>With hyperkalaemia, or taking medication that is known to cause hyperkalaemia.</li><li>With acute porphyria.</li><li>Predisposed to folate deficiency — because of the potential anti-folate effect of trimethoprim, there is a risk of further exacerbating folate deficiency in people who are folate deficient, or who are predisposed to folate deficiency (for example elderly people), or who are taking folate antagonists.</li></ul></li></ul><p><strong>Adverse effects </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Arnold, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">BNF 76, 2018</a>]</p><ul><li>Blood disorders — leucopenia, megaloblastic anaemia, thrombocytopenia, agranulocyctosis, methaemoglobinaemia.</li><li>Gastrointestinal — diarrhoea, nausea, vomiting, glossitis.</li><li>Nervous system — aseptic meningitis (frequency unknown), headache.</li><li>Skin — Pruritus, and skin rashes (common).<ul><li>Rarely: Photosensitivity, exfoliative dermatitis, fixed drug eruption, erythema multiforme, erythema nodusum, Stevens-Johnson Syndrome, toxic epidermal necrolysis, bullous dermatitis, purpura, angioedema.</li></ul></li><li>Other adverse effects include:<ul><li>Anaphylaxis.</li><li>Liver enzyme disturbances, cholestatic jaundice.</li><li>Myalgia.</li><li>Raised serum creatinine and electrolyte disturbance such as hyperkalaemia (particularly in the elderly and in HIV patients),</li></ul></li></ul><p><strong>Drug interactions </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">FSRH, 2017</a>]</p><ul><li>Aciclovir — increased risk of nephrotoxicity.</li><li>Amitryptaline — increased risk of hyponatraemia.</li><li>Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-II receptor antagonists AIIRAs — there may be an increased risk of hyperkalaemia with the concurrent use of these drugs and trimethoprim. Monitor potassium concentrations.</li><li>Azathioprine and mercaptopurine — increased risk of haematological toxicity in people who have had a renal transplant. However, the combination is commonly used in practice. Monitor the full blood count routinely.</li><li>Carbamazepine — increased risk of hyponatraemia.</li><li>Ciclosporin — serum creatinine levels may be increased. Possible increased risk of nephrotoxicity. Increased risk of hyperkalaemia. Monitor renal function closely.</li><li>Citalopram, escitalopram, fluoxetine and sertraline — increased risk of hyponatraemia.</li><li>Coumarins (warfarin) — the anticoagulant effect of coumarins may be potentiated. Monitor international normalised ratio (INR) and adjust dose accordingly.</li><li>Dapsone — dapsone increases the exposure to trimethoprim and trimethoprim increases the exposure to dapsone.</li><li>Digoxin — digoxin levels may be increased in the elderly if taken with trimethoprim. Monitor for digoxin adverse effects, and adjust dose accordingly.</li><li>Diuretics — hyperkalaemia may be exacerbated by concomitant administration of diuretics, particularly potassium sparing diuretics and/or thiazide diuretics and eplerenone.</li><li>Mefenamic acid — increased risk of hyponatraemia, hyperkalaemia and nephrotoxicity.</li><li>Methotrexate (a folate antagonist) — there is an increased risk of haematologic adverse effects. Several cases of bone marrow suppression have been reported (some fatal). Full blood count should be monitored routinely.</li><li>NSAIDS — increased risk of hyponatraemia, hyperkalaemia and nephrotoxicity.</li><li>Oral hormonal contraception — additional contraceptive precautions are not required during or after courses of trimethoprim. However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea.<ul><li>For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li>Phenytoin – phenytoin levels may be increased if taken with trimethoprim. Monitor phenytoin levels and adjust dose accordingly.</li></ul><p><strong>Monitoring</strong> <strong>and patient/carer advice</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">BNF 76, 2018</a>]</p><ul><li>Manufacturer recommends blood counts on long-term therapy.</li><li>On long-term treatment, patients and their carers should be told how to recognise signs of blood disorders and advised to seek immediate medical attention if symptoms such as fever, sore throat, rash, mouth ulcers, purpura, bruising or bleeding develop.</li></ul><p><strong>Pregnancy and breastfeeding </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">UKTIS, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">ACOG, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NPIS, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urinary-tract-infection-lower-women/references/\">NICE, 2018d</a>]</p><ul><li><strong>Pregnancy</strong><ul><li>There is a teratogenic risk in the first trimester of pregnancy (folate antagonist). The manufacturer advises that it should not be used in women who are pregnant.</li><li>Trimethoprim should not be administered to pregnant women, premature infants or infants during the first few weeks of life — seek specialist advice.</li></ul></li><li><strong>Breastfeeding</strong><ul><li>Trimethoprim is excreted in breastmilk, short-term use is not known to be harmful.</li></ul></li></ul><!-- end field acc42167-c396-4efa-8142-a71c00abb219 --><!-- end item 39bd7280-e58a-4aa3-acdf-a71c00abb25a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}